Dalton Announces a Drug Development & GMP Manufacturing Services Agreement With Oryn Therapeutics

Dalton Pharma Services has recently announced the signing of a drug development and manufacturing services agreement with Oryn Therapeutics, an American biotechnology firm committed to the clinical development of novel and affordable drugs to address unmet medical needs in autoimmunity, inflammation and infectious diseases.

Under the signed agreement, Dalton will provide drug development and cGMP aseptic liquid filling of ORTD-1 in glass vials which will be used for Phase-1 clinical studies of ORTD-1 by the 3rd quarter of this year.

ORTD-1 is a first-in-class drug for treatment of rheumatoid arthritis (RA). RA affects about 1% of the population worldwide. It is the third most common type of arthritis and causes more disability than any other condition, including heart disease, diabetes, and back/spine problems. Due to its severely debilitating nature in advanced stages, it accounts for 22% of all deaths from arthritis and other rheumatic conditions. ORTD-1 treatment of experimental arthritis in rats has been shown to induce remission of established disease after only 9 days of treatment. The remission is long lasting (2 to 3 months) after treatment is discontinued.

“Dalton is privileged to be associated with Oryn in its commitment to develop a safe and effective first-in-class drug treatment for RA”, said Peter Pekos, CEO and President, Dalton Pharma Services.

Oryn is a biopharmaceutical company leveraging its proprietary knowledge and paradigm changing approach to drug development utilizing the structural and biologic properties of theta defensins, cyclic peptides that evolved over billions of years to develop novel therapies to address the unmet medical needs in autoimmunity, inflammation and infectious diseases. They are the industry leaders in R&D of theta defensins and development of methods for synthetic and recombinant production of macrocyclic Orynotides, peptide derivatives of macrocyclic theta defensins that are stable, non-toxic, non-immunogenic and non-immunosuppressive. Oryn has developed and patented a technology that gives it a technical edge in the design, functional analysis, and production of Orynotides. These efforts have uniquely positioned Oryn to develop new classes of clinically valuable therapeutics. For more information, visit http://www.oryntherapeutics.com.

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada-approved and FDA-registered cGMP contract service provider of integrated chemistry, drug development, and manufacturing services to the pharmaceutical and biotechnology industries. We bring 30 years of experience to our client’s projects and emphasize quality, speed and flexibility. Dalton can accelerate your drug development program by integrating process development, cGMP API manufacturing, cGMP sterile fill/finish, and solid finished dose manufacturing, all at a single location. For more information, visit https://www.dalton.com.